NEW YORK, March 28, 2017 /PRNewswire/ --
This morning's research on Stock-Callers.com draws investors' attention to these four stocks: The Medicines Co. (NASDAQ:
MDCO), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Supernus Pharmaceuticals
Inc. (NASDAQ: SUPN). These companies operate in the Generic Drugs space which is governed by the same governing framework as
branded drugs. The key growth drivers for the industry are wholesalers, retailers, pharmacies, and benefit
managers. Learn more about these stocks by downloading their free report at:http://stock-callers.com/registration
Medicines
On Monday, shares in Parsippany, New Jersey-based The Medicines Co. recorded a trading volume
of 903,995 shares. The stock ended the session 0.43% higher at $50.91. The Company's shares have
surged 47.27% over the previous three months and 50.00% on an YTD basis. The stock is trading 9.31% above its 50-day moving
average and 30.80% above its 200-day moving average. Moreover, shares of Medicines Co., which provides medicines for patients in
acute and intensive care hospitals worldwide, have a Relative Strength Index (RSI) of 55.31.
On February 28 th, 2017, Medicines Co. announced its financial results for Q4 2016
and full year ended December 31 st, 2016. For Q4, worldwide net revenue was $25.2 million, and net loss from continuing operations was $124.4 million. For
full year 2016, worldwide net revenue was $167.8 million, and net loss from continuing operations
was $119.4 million. The free research report on MDCO is available at:
http://stock-callers.com/registration/?symbol=MDCO
Ironwood Pharma
Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc.'s stock closed the day
0.18% higher at $17.17, with a total trading volume of 984,156 shares. The Company's shares have
advanced 4.57% in the past month, 11.71% in the previous three months, and 12.30% since the start of this year. The stock is
trading 5.33% and 15.53% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Ironwood Pharma,
which engages in the research, development, and commercialization of human therapeutic products, have an RSI of 56.06. The
complimentary report on IRWD can be downloaded at: http://stock-callers.com/registration/?symbol=IRWD
Pacira Pharma
Shares in Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc. recorded a trading
volume of 575,439 shares. The stock ended yesterday's trading session 1.39% higher at $47.55. The
Company's shares have advanced 9.44% in the past month, 50.47% in the last three months, and 47.21% on an YTD basis. The stock is
trading above its 50-day and 200-day moving averages by 8.88% and 23.66%, respectively. Furthermore, shares of Pacira Pharma,
which develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and
ambulatory surgery centers in the US, have an RSI of 55.88.
On March 16 th, 2017, Pacira Pharmaceuticals and Trinity Health announced that they
will collaborate to develop an alternative approach to opioids for pain management. In their collaboration, the duo will work to
improve the overall patient-recovery experience and decrease the threat of long-term opioid risks, which include misuse, abuse,
and addiction.
On March 23 rd, 2017, research firm Mizuho reiterated its 'Buy' rating on the
Company's stock with a decrease of the target price from $59 a share to $54 a share. Visit us today and download our complete research report on PCRX for free at:http://stock-callers.com/registration/?symbol=PCRX
Supernus Pharma
Rockville, Maryland-based Supernus Pharmaceuticals Inc.'s stock finished Monday's session
2.84% higher at $30.80. A total volume of 904,383 shares was traded, which was above their three
months average volume of 543,970 shares. The Company's shares have advanced 21.74% in the last one month, 23.69% over the
previous three months, and 21.98% since the start of this year. The stock is trading above its 50-day and 200-day moving averages
by 16.54% and 32.07%, respectively. Additionally, shares of Supernus Pharma, which focuses on the development and
commercialization of products for the treatment of central nervous system diseases in the US, have an RSI of 63.20.
On March 07 th, 2017, Supernus Pharmaceuticals announced that it has entered into a
binding term sheet with Actavis Laboratories, Florida, Inc. et al. involving the ongoing patent
litigation regarding Actavis' Abbreviated New Drug Application seeking approval to market generic versions of Supernus Pharma's
Trokendi XR® capsules. The binding term sheet permits Actavis to begin selling a generic version of Trokendi
XR® on January 01 st, 2023 or earlier under certain circumstances. Get free access
to your technical report on SUPN at:http://stock-callers.com/registration/?symbol=SUPN
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES :
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information,
visithttp://stock-callers.com/legal-disclaimer/
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone
between 09:30 EDT to 16:00 EDT from Monday to Friday.
SOURCE Chelmsford Park SA